All these data suggested that the knockdown of NOP2 obviously inhibits both growth and metastasis of HCT116‐derived xenografts in vivo, indicating that NOP2 holds the potential to be used as a therapeutic target in adjuvant CRC therapy. This evidence concerns the gene NOP2 and colorectal carcinoma.